Goldstein, O., Shani, S., Gana-Weisz, M., Elkoshi, N., Casey, F., Sun, Y. H., Chandratre, K., Cedarbaum, J. M., Blauwendraat, C., Bar-Shira, A., Thaler, A., Gurevich, T., Mirelman, A., Giladi, N., Orr-Urtreger, A., & Alcalay, R. N. (2025). The effect of polygenic risk score on PD risk and phenotype in LRRK2 G2019S and GBA1 carriers. Journal of Parkinson’s Disease. https://doi.org/10.1177/1877718x241310722

Shani, S., Gana-Weisz, M., Bar-Shira, A., Thaler, A., Gurevich, T., Mirelman, A., Giladi, N., Alcalay, R. N., Orr-Urtreger, A., & Goldstein, O. (2024). P2RX7, an adaptive immune response gene, is associated with Parkinson’s disease risk and age at onset. Journal of Parkinson’s Disease. https://doi.org/10.1177/1877718x241296015

Smilowska, K., Mehanna, R., Fleisher, J. E., Alcalay, R. N., Kumar, K. R., Marras, C., Oosterbaan, A. M., Post, B., Ross, O. A., Pimentel Piemonte, M. E., Fraix, V., Moro, E., King Tan, E., & Savica, R. (2024). Unmet Need in Early-Onset Parkinson’s Disease: Deep Brain Stimulation and Pregnancy. Journal of Parkinson’s Disease, 1–6. https://doi.org/10.3233/jpd-240088

Keavney, J. L., Mathur, S., Schroeder, K., Merrell, R., Castillo-Torres, S. A., Gao, V., Crotty, G. F., Schwarzschild, M. A., & Poma, J. M. (2024). Perspectives of People At-Risk on Parkinson’s Prevention Research. Journal of Parkinson’s Disease, 14(3), 399–414. https://doi.org/10.3233/jpd-230436

Ré, D. B., & Rideout, H. J. (2023). Why the Gut Microbiome Must Be Considered When Evaluating the Impact of Pesticides on Parkinson’s Disease Risk. Journal of Parkinson’s Disease, 13(7), 1077–1078. https://doi.org/10.3233/jpd-239004

Pachi, I., Papadopoulos, V., Koros, C., Simitsi, A. M., Bougea, A., Bozi, M., Papagiannakis, N., Soldatos, R. F., Kolovou, D., Pantes, G., Scarmeas, N., Paraskevas, G., Voumvourakis, K., Papageorgiou, S. G., Kollias, K., Stefanis, N., & Stefanis, L. (2023). Comprehensive Evaluation of Psychotic Features and Their Clinical Correlates in Early Parkinson’s Disease. Journal of Parkinson’s Disease, 13(7), 1185–1197. https://doi.org/10.3233/jpd-230056

Wilkins, K. B., Petrucci, M. N., Kehnemouyi, Y., Velisar, A., Han, K., Orthlieb, G., Trager, M. H., O’Day, J. J., Aditham, S., & Bronte-Stewart, H. (2022). Quantitative Digitography Measures Motor Symptoms and Disease Progression in Parkinson’s Disease. Journal of Parkinson’s Disease, 12(6), 1979–1990. https://doi.org/10.3233/jpd-223264

Hobson, B. D., & Sulzer, D. (2022). Neuronal Presentation of Antigen and Its Possible Role in Parkinson’s Disease. Journal of Parkinson’s Disease, 12(s1), S137–S147. https://doi.org/10.3233/jpd-223153

Peterschmitt, M. J., Saiki, H., Hatano, T., Gasser, T., Isaacson, S. H., Gaemers, S. J. M., Minini, P., Saubadu, S., Sharma, J., Walbillic, S., Alcalay, R. N., Cutter, G., Hattori, N., Höglinger, G. U., Marek, K., Schapira, A. H. V., Scherzer, C. R., Simuni, T., … Fischer, T. Z. (2022). Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson’s Disease, 12(2), 557–570. https://doi.org/10.3233/jpd-212714